Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CureFAKtor Pharmaceuticals has received Orphan Drug Designation (ODD) for its treatment of pancreatic cancer, CFAK-C4 from the US Food and Drug Administration (FDA).
Subscribe to our email newsletter
CureFAKtor Pharma is intending to conduct a Phase I clinical study of CFAK-C4 in combination with gemcitabine chemotherapy in 2012.
CureFAKtor Pharma president and CEO Shep Wild said receiving Orphan Drug Designation by the FDA is an important milestone for CureFAKtor, as well as for pancreatic cancer patients who have the lowest survival rate of any cancer and limited treatment options.
"CFAK-C4 is the first clinical candidate derived from our broad FAK technology platform and we look forward to progressing CFAK-C4 into human clinical trials," Wild said.